Deferred Cytoreductive Nephrectomy Plus Sunitinib Bests Immediate Surgery in RCCSeptember 22nd 2020
In a post hoc analysis of the randomized phase 3 SURTIME trial of patients with metastatic renal cell carcinoma, early treatment with sunitinib demonstrated better control over the disease as well as detection of progression before planned cytoreductive nephrectomy.
Ongoing Minority Underrepresentation in Clinical Research Leads to Efforts to Bridge the DivideSeptember 22nd 2020
Inequities in patient enrollment to cancer clinical trials has once again bubbled to the surface of cancer conversations, resulting in collaboration between clinicians to address and overcome the barriers observed
Investigators Attempt to Uncover Basis Behind Sexual Dysmorphic and Age-Related Responses to ImmunotherapySeptember 17th 2020
An analysis of patient samples from The Cancer Genome Atlas indicated a possible connection between tumor responses to immunotherapy and patient baseline characteristics after investigators discovered evidence of stronger immune selection by female and younger patients in early tumorigenesis.
Previous Liver Infection Requires a Rapid and Flexible Treatment Response in NSCLCSeptember 16th 2020
Jorge A. Rios, MD, a medical oncologist at Zangmeister Cancer Center in Columbus, Ohio, part of the American Oncology Network, shared the case of a woman who developed multiple severe adverse events attributable to durvalumab.